|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||4.60 - 6.90|
|52 Week Range||1.20 - 6.90|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The major side effect of RD is skin tissue damage also known as radiodermatitis which occurs in 95% of cancer patients receiving radiation therapy (RT). While acute inflammation is observed within hours of RT, this painful and common side effect develops over weeks and its severity with time progresses to erythema, dry or wet desquamation or ulceration.
Research recently published in the Journal of Molecular Neuroscience showed that KLS-13019 was 200 times more potent, 10 times more bioavailable, 5 times safer and 1000 times more effective than CBD.
Medical Marijuana, Inc. (the "Company") (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its portfolio investment company Kannalife, Inc. ("Kannalife") (OTC: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, officially commenced trading on the OTC Markets under the ticker symbol "KLFE." Medical Marijuana, Inc. became Kannalife's original investor in 2013 and currently owns approximately 26.17% common equity in the company.
Kannalife has developed its own patented intellectual property estate of molecules led by KLS-13019, the company’s novel CBD-like molecule to treat neurodegenerative, chronic pain management and oxidative stress-related diseases. Kannalife has made significant improvements in the chemistry and efficacy of their new CBD-like molecules.